Drug Trial Radar · NCT05242133
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Oct 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168
Actual
Start
Dec 20, 2017
Primary completion
Apr 27, 2022
Study completion Apr 27, 2022
Sponsor
- Lead sponsor
- CinnagenIndustry
- Sponsor type
- Industry
- First posted
- Feb 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of peginterferon beta-1a produced by CinnaGen compared with CinnoVex® (CinnaGen) in subjects with relapsing remitting multiple sclerosis (RRMS). All the participants will receive one of the following regimens: pegylated interferon beta-1a (CinnaGen), autoinjector (Physioject™), 125mcg, subcutaneous, every 2 weeks for 24 months or CinnoVex® (CinnaGen), prefilled syringes, 30mcg, intramuscular, once a week for 24 months. The primary objective of this study is to verify the non-inferiority of peginterferon beta-1a (CinnaGen) versus CinnoVex® (CinnaGen) in reducing the annualized relapse rate (ARR) in participants with relapsing remitting multiple sclerosis (RRMS) at 2 years. The secondary objectives of this study are: * Reducing the total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance imaging (MRI) scans * Slowing the progression of disability * Comparing adverse events
Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions
Pegylated interferon beta-1aDrug
Pegylated interferon beta-1a (CinnaGen) autoinjector (Physioject™),125 mcg, subcutaneous (SC) injection, every 2 weeks, for 24 months
Interferon Beta-1A Prefilled SyringeDrug
Interferon Beta-1A Prefilled Syringe, CinnoVex® (CinnaGen), 30 mcg, intramuscular injection, once a week, for 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse RateTime frame: 96 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sina Hospital
Tehran, Iran
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.